Unicycive Therapeutics, Inc. (UNCY) intrinsic value & 10-year financials
Unicycive Therapeutics, Inc. (UNCY) has a Graham intrinsic value of $71.38 per share. At $3.36 on Oct 17, 2026, the stock trades 95% below that value.
- Graham intrinsic value
- $71.38
- Share price (Oct 17, 2026)
- $3.36
- Price vs Graham value
- 95% below
- Market cap
- $53.4M
- Revenue (FY2025)
- —
- Revenue growth (7-yr CAGR)
- -29.0%
- ROIC (10-yr avg)
- -7675.9%
- Free cash flow (FY2025)
- -$31.3M
UNCY 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$26.6M | -$1.67 | -$31.3M | — | 142.8% |
| FY2024 | — | -$36.7M | -$0.56 | -$28.6M | — | 232.2% |
| FY2023 | $675.0K | -$30.5M | -$1.28 | -$18.3M | -3077.6% | 234.2% |
| FY2022 | $951.0K | -$18.1M | -$1.20 | -$15.7M | -1898.2% | -30096.7% |
| FY2021 | — | -$10.0M | -$0.86 | -$5.8M | — | -16695.0% |
| FY2020 | — | -$2.3M | — | — | — | 127.4% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Unicycive Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Unicycive Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -32.2% ROIC.
Unicycive Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Unicycive Therapeutics, Inc. is modeled at -29.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $71.38 per share.